Corrective Phases R...
Health Care: Drugs
Agenus Inc. (AGEN: NASDAQ)
$2.48 0.06 | 2.48%
12/01/11 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 10.75M | 19.78M | 20.07M | 24.47M |
| Receivables | 0.00 | 35.00K | 0.00 | 0.00 |
| Inventories | 20.07K | 26.43K | 324.04K | 226.38K |
| Other Current Assets | 699.79K | 306.01K | 391.72K | 187.01K |
| Total Current Assets | 12.00M | 20.85M | 31.53M | 35.49M |
| Property, Plant & Equipment, Gross | 30.22M | 31.19M | 37.50M | 37.42M |
| Accumulated Depreciation & Depletion | 26.08M | 24.99M | 28.61M | 25.88M |
| Property, Plant & Equipment, Net | 4.14M | 6.19M | 8.89M | 11.54M |
| Intangibles | 0.00 | 29.84K | 1.61M | 3.27M |
| Other Non-Current Assets | 1.09M | 1.26M | 1.26M | 4.08M |
| Total Non-Current Assets | 7.80M | 10.05M | 14.34M | 21.46M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 19.81M | 30.91M | 45.87M | 56.95M |
| Accounts Payable | 807.93K | 698.55K | 895.34K | 540.53K |
| Short Term Debt | 197.68K | 146.06K | 146.06K | 146.06K |
| Other Current Liabilities | 475.34K | 346.31K | 214.59K | 209.58K |
| Total Current Liabilities | 4.75M | 5.42M | 5.35M | 7.00M |
| Long Term Debt | 32.73M | 34.05M | 49.49M | 67.84M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 3.16M | 6.15M | 8.00M | 6.03M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 41.46M | 40.20M | 57.49M | 73.87M |
| Total Liabilities | 46.22M | 45.61M | 62.85M | 80.86M |
| Preferred Stock Equity | 347.00 | 347.00 | 347.00 | 369.00 |
| Common Stock Equity | -26.41M | -14.71M | -16.98M | -23.92M |
| Common Par | 215.35K | 1.12M | 900.15K | 664.98K |
| Additional Paid In Capital | 581.39M | 568.92M | 544.96M | 503.02M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -607.69M | -584.42M | -562.51M | -527.34M |
| Treasury Stock | -324.79K | -324.79K | -324.79K | -269.85K |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 6.31M | 19.34M | 32.52M | 43.92M |
| Total Equity | -26.41M | -14.71M | -16.97M | -23.92M |
| Total Liabilities & Stock Equity | 19.81M | 30.91M | 45.87M | 56.95M |
| Total Common Shares Outstanding | 21.49M | 18.60M | 14.96M | 11.13M |
| Preferred Shares | 34.72K | 34.72K | 34.72K | 36.87K |
| Treasury Shares | 43.49K | 43.49K | 43.49K | 0.00 |
| Basic Weighted Shares Outstanding | 19.90M | 16.11M | 13.17M | 10.54M |
| Diluted Weighted Shares Outstanding | 19.90M | 16.11M | 13.17M | 10.54M |
| Number of Employees | 54 | 56 | 54 | 80 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with AGEN
- Portfolio NameUser Type
- UserKJP Save Stockpickr Fund
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Contributor16 Small-Cap Stocks in Dang...
- UserASCO 2010
- Userhp22puch Portfolio 1
- Usernvoelz Portfolio 1
- UserPix's Stocks
- UserArsenD Portfolio 1
- UserMikejo10 Portfolio 1
Latest AGEN Headlines from TheStreet
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 3 Stocks Under $10 Moving Higher 03.29.12 | 12:03 pm
- Agenus' CEO Discusses Q4 2011 Results - Earnings Call Transcript 03.05.12 | 03:03 pm
- Agenus Only Gets A Mosquito-Sized Bite of the New And Heralded Malaria Vaccine 10.18.11 | 03:10 pm
- Agenus Stock Gaps Down On Today's Open (AGEN) 10.07.11 | 09:10 am
- Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.29.11 | 10:07 pm
- Oncothyreon: Deep Dive Into Stimuvax 07.11.11 | 07:07 am
- Biotech Data Mining Comes Up Empty 06.29.11 | 07:06 am
- ASCO: Cancer Stock Winners, Losers 05.19.11 | 10:05 am
- Agenus Receives NASDAQ Delisting Notification 03.04.11 | 09:03 am
Press Releases for AGEN
- The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical Development - Business Wire 08.25.10 | 02:08 pm
- Antigenics Reports Second Quarter 2010 Financial Results - Business Wire 07.29.10 | 07:07 am
- Antigenics Presents Positive, Top Line Data From Phase I Herpes Clinical Trial - Business Wire 07.27.10 | 07:07 am
- Antigenics To Report Second Quarter Financial Results On July 29, 2010; Conference Call To Follow - Business Wire 07.22.10 | 07:07 am
- Antigenics Receives NASDAQ Delisting Notification - Business Wire 07.21.10 | 04:07 pm
- Encouraging Data Presented On Oncophage® Vaccine At International Conference On Brain Tumor Research And Therapy - Business Wire 05.20.10 | 07:05 am
- Antigenics To Webcast 2010 Annual Shareholders Meeting - Business Wire 04.29.10 | 07:04 am
- Antigenics Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 07:04 am
- Antigenics To Report First Quarter Financial Results On April 29, 2010; Conference Call To Follow - Business Wire 04.22.10 | 07:04 am
- Antigenics To Report Fourth Quarter And Year-End 2009 Financial Results On February 18, 2010; Conference Call To Follow - Business Wire 02.11.10 | 07:02 am
Partner Headlines for AGEN
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 05.17.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 05.14.12 | 09:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Market Update - Benzinga 03.20.12 | 09:03 am
- Agenus Continues to Outperform - Seeking Alpha 03.16.12 | 06:03 pm
- 7 Biotech Stocks Being Snapped Up By Insiders - Seeking Alpha 03.16.12 | 05:03 pm
- Agenus Still Gaining On GSK Agreement Expansion - Seeking Alpha 03.15.12 | 08:03 am
- Insider Buys May Send The Wrong Signals - Seeking Alpha 08.22.11 | 09:08 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- Antigenics changes name to Agenus - Reuters 01.06.11 | 01:01 pm
